Solving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages

  Vöhringer, Paul A ^a,b   Ghaemi, S Nassir ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Effect size; Meta analysis; Randomized clinical trials

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

DATA BASE; DRUG EFFICACY; EFFECT SIZE; FOOD AND DRUG ADMINISTRATION; MAJOR DEPRESSION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 83455225434     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.11.019     Document Type: Review

References (23)

1. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
2. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 2008, 5:e45.
3. Ioannidis J.P. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. Philos Ethics Humanit Med 2008, 3:14.
4. Geddes J.R., Freemantle N., Mason J., et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2006, (3). CD001851.
5. Kornstein S.G., Kocsis J.H., Ahmed S., et al. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. Int Clin Psychopharmacol 2008, 23:357-363.
6. Andrews P.W., Kornstein S.G., Halberstadt L.J., et al. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011, 2:159.
7. Turner E.H., Matthews A.M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
8. Horder J., Matthews P., Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2010 Jun 22, [Epub ahead of print].
9. Handbook of Psychiatric Measures 2000, American Psychiatric Press, Washington, DC. A.J. Rush, M.B. First, D. Blacker (Eds.).
10. Schmitt A.B., Bauer M., Volz H.P., et al. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 2009, 259:329-339.
11. Montgomery S.A., Lecrubier Y. Is severe depression a separate indication?. ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999, 9:259-264.
12. Feinberg M., Carroll B.J., Smouse P.E., Rawson S.G. The Carroll rating scale for depression. III. Comparison with other rating instruments. Br J Psychiatry 1981, 138:205-209.
13. Fountoulakis K.N., Möller H.J. Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. J Psychopharmacol 2011 Sep 17, [Epub ahead of print].
14. Davis J.M., Giakas W.J., Qu J., et al. Should we treat depression with drugs or psychological interventions?. A reply to Ioannidis. Philos Ethics Humanit Med 2011, 6:8.
15. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40. STAR*D Study Team.
16. Kraepelin E. Manic-Depressive Insanity and Paranoia 1921, Barclay RM, trans, E & S Livingstone, Edinburgh, UK. G.M. Robertson (Ed.).
17. Frank E., Kupfer D.J., Perel J.M., et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990, 47:1093-1099.
18. Goodwin F., Jamison K. Manic Depressive Illness 2007, Oxford University Press, New York, NY. 2nd ed.
19. Goodwin F.K., Whitham E.A., Ghaemi S.N. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers?. CNS Drugs 2011, 25:819-827.
20. Suppes T., Baldessarini R.J., Faedda G.L., Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991, 48:1082-1088.
21. Cavanagh J., Smyth R., Goodwin G.M. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004, 109:91-95.
22. Briscoe B.E., El-Mallakh R.S. The evidence for the long-term use of antidepressants as prophylaxis against future depressive episodes. Oral presentation at the American Psychiatric Association Annual Meeting May 22-26, 2010.
23. Kocsis J.H., Thase M.E., Trivedi M.H., et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry 2007, 68:1014-1023.